Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 29;14(8):802.
doi: 10.3390/jpm14080802.

Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis

Amin Jahanbakhshi  1 , Masoumeh Najafi  1 , Marzieh Gomar  2 , Patrizia Ciammella  3 , Maria Paola Ruggieri  3 , Cinzia Iotti  3 , Sebastiano Finocchi Ghersi  3 , Anne-Agathe Serre  4 , Lilia Bardoscia  5 , Angela Sardaro  6 , Sophie Boisbouvier  4 , Camille Roukoz  4 , Salvatore Cozzi  4
Affiliations
Review

Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis

Amin Jahanbakhshi et al. J Pers Med. .

Abstract

Background: Meningiomas are the most prevalent benign intracranial tumors. When they are of the invasive subtypes, i.e., grades II and III, they can recur rapidly and present a real challenge for physicians. This study is focused on the use of stereotactic radiosurgery to manage high-grade meningiomas.

Method: Medline via PubMed was searched from inception to December 2022 to retrieve studies on stereotactic radiation therapy for patients with grade II-III meningiomas. This study was conducted under PRISMA guidelines.

Result: A total of 29 articles involving 1446 patients with grade II-III meningiomas treated with stereotactic radiation therapy were included in the present study. Of these studies, 11 were conducted exclusively on patients with atypical meningiomas (grade II), 1 targeted anaplastic meningiomas (grade III), and 17 articles were carried out on both grade II and III meningiomas. The pooled 1, 2, 3, 5, and 10-year overall survival (OS) of grade II meningiomas was 0.96 [p < 0.01], 0.89 [p = 0.01], 0.90 [p = 0.09], 0.81 [p < 0.01], and 0.66 [p = 0.55], respectively. The pooled 2, 5, and 10-year OS of grade III meningiomas was 0.64 [p = 0.01], 0.41 [p = 0.01], and 0.19 [p < 0.01], respectively.

Conclusions: Although long-term prospective studies are still required, the outcomes of stereotactic radiation therapy appear promising regarding overall outcome and progression-free survival.

Keywords: SBRT; grade II and III meningiomas; literature review; meningiomas; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The PRISMA flowchart.
Figure 2
Figure 2
1-, 2-, 3-, 5-, and 10-year PFS analysis of WHO grade II meningiomas.
Figure 3
Figure 3
1-, 2-, 3-, 5-, and 10-year OS analysis of WHO grade II meningiomas.
Figure 4
Figure 4
1-, 2-, 3-, 5-, and 10-year PFS analysis of WHO grade III meningiomas.
Figure 5
Figure 5
1-, 2-, 3-, 5-, and 10-year OS analysis of WHO grade III meningiomas.
See this image and copyright information in PMC

References

    1. Kaul D., Budach V., Wurm R., Gruen A., Graaf L., Habbel P., Badakhshi H. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. Radiat. Oncol. 2014;9:78. doi: 10.1186/1748-717X-9-78. - DOI - PMC - PubMed
    1. Claus E.B., Bondy M.L., Schildkraut J.M., Wiemels J.L., Wrensch M., Black P.M. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088–1095. doi: 10.1227/01.NEU.0000188281.91351.B9. - DOI - PubMed
    1. Qiu L.H., Lui S., Zou L., Yue Q., Gong Q.Y. Lateral ventricular cystic meningioma: 2 rare case reports. Exp. Ther. Med. 2014;7:1393–1395. doi: 10.3892/etm.2014.1550. - DOI - PMC - PubMed
    1. Kitamura Y., Akiyama T., Sasaki H., Hayashi Y., Yoshida K. Optic nerve seeding of atypical meningiomas presenting with subacute visual loss: 2 case reports with genetic characterization: Report of 2 cases. J. Neurosurg. 2013;119:494–498. doi: 10.3171/2013.1.JNS121533. - DOI - PubMed
    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed

LinkOut - more resources